Company: STAA
Filing Date: 2025-09-22
Form Type: DEFA14A
Source: 0001193125-25-210031
Chunk: 0

Company: STAAR SURGICAL CO
Filing Date: 2025-09-22
Form: DEFA14A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box:

| ☐ | Preliminary Proxy Statement |

| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |

| ☐ | Definitive Proxy Statement |

| ☒ | Definitive Additional Materials |

| ☐ | Soliciting Material under § 240.14a-12 |

STAAR SURGICAL COMPANY (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box):

| ☒ | No fee required. |

| ☐ | Fee paid previously with preliminary materials. |

| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11. |

On September 22, 2025, STAAR Surgical Company (“STAAR”) issued the following press release: STAAR Surgical Announces Expiration of “Window Shop” Period; No Competing Acquisition Proposals Received Reinforces STAAR Board’s Determination that Alcon Merger Maximizes Stockholder Value and is Best Path Forward for STAAR Stockholders LAKE FOREST, CA, September 22, 2025—- STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer ®Lenses (EVO ICL ™) for vision correction, today announced the expiration of the 45-day“window shop” period under the terms of the previously announced merger agreement with affiliates of Alcon (SIX/NYSE: ALC). The “window shop” period expired at 11:59 p.m., Eastern Time, on September 19, 2025, and no competing acquisition proposal was received despite Broadwood Partners’ active exploration of alternative buyers over the past 45 days. “The expiration of the ‘window shop’ period with no competing acquisition proposal reinforces the Board’s conclusion that the Alcon merger maximizes value for STAAR stockholders,” said Stephen Farrell, CEO of